TY - JOUR
T1 - The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure
AU - for the Multi-Organ Dysfunction and Evaluation for Liver Transplantation (MODEL) Consortium
AU - Hernaez, Ruben
AU - Karvellas, Constantine J.
AU - Liu, Yan
AU - Sacleux, Sophie Caroline
AU - Khemichian, Saro
AU - Stein, Lance L.
AU - Shetty, Kirti
AU - Lindenmeyer, Christina C.
AU - Boike, Justin R.
AU - Simonetto, Douglas A.
AU - Rahimi, Robert S.
AU - Jalal, Prasun K.
AU - Izzy, Manhal
AU - Kriss, Michael S.
AU - Im, Gene Y.
AU - Lin, Ming V.
AU - Jou, Janice H.
AU - Fortune, Brett E.
AU - Cholankeril, George
AU - Kuo, Alexander
AU - Mahmud, Nadim
AU - Kanwal, Fasiha
AU - Saliba, Faouzi
AU - Sundaram, Vinay
AU - Artzner, Thierry
AU - Jalan, Rajiv
AU - Al Attar, Atef
AU - Kosari, Kambiz
AU - Garcia, Richard
AU - Salmastyan, Gevork
AU - Cranford, William
AU - Patel, Preet
AU - Xue, Pei
AU - Mishra, Soumya
AU - Parks, Madison
AU - Flocco, Gianina
AU - Gao, Jing
AU - Wu, Tiffany
AU - Thanneeru, Priya
AU - Reddy, Vikrant
AU - Hurtado, Mariana
AU - Mohamed, Islam
AU - Vyhmeister, Ross
AU - Lopez, Christine R.
AU - Campbell, Braidie
AU - Winters, Adam C.
AU - Simpson, Mary Ann
AU - Ying, Xiaohan
N1 - Publisher Copyright:
© 2023
PY - 2023/9
Y1 - 2023/9
N2 - Background & Aims: Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS). Methods: In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan’2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors. Results: We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age >50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS. Conclusions: The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits. Impact and implications: Liver transplantation (LT) may be the only life-saving procedure available to patients with acute-on-chronic liver failure (ACLF), but clinically instability can augment the perceived risk of post-transplant mortality at 1 year. We developed a parsimonious score with clinically and readily available parameters to objectively assess 1-year post-LT survival and predict median length of stay after LT. We developed and externally validated a clinical model called the Sundaram ACLF-LT-Mortality score in 521 US patients with ACLF with 2 or ≥3 organ failure(s) and 120 French patients with ACLF grade 3. The c-statistic was 0.72 in the development cohort and 0.80 in the validation cohort. We also provided an estimation of the median length of stay after LT in these patients. Our models can be used in discussions on the risks/benefits of LT in patients listed with severe ACLF. Nevertheless, the score is far from perfect and other factors, such as patient's preference and center-specific factors, need to be considered when using these tools.
AB - Background & Aims: Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS). Methods: In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan’2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors. Results: We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age >50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS. Conclusions: The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits. Impact and implications: Liver transplantation (LT) may be the only life-saving procedure available to patients with acute-on-chronic liver failure (ACLF), but clinically instability can augment the perceived risk of post-transplant mortality at 1 year. We developed a parsimonious score with clinically and readily available parameters to objectively assess 1-year post-LT survival and predict median length of stay after LT. We developed and externally validated a clinical model called the Sundaram ACLF-LT-Mortality score in 521 US patients with ACLF with 2 or ≥3 organ failure(s) and 120 French patients with ACLF grade 3. The c-statistic was 0.72 in the development cohort and 0.80 in the validation cohort. We also provided an estimation of the median length of stay after LT in these patients. Our models can be used in discussions on the risks/benefits of LT in patients listed with severe ACLF. Nevertheless, the score is far from perfect and other factors, such as patient's preference and center-specific factors, need to be considered when using these tools.
KW - ACLF
KW - liver transplantation
KW - prognosis
KW - risk score
UR - http://www.scopus.com/inward/record.url?scp=85166939589&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2023.05.028
DO - 10.1016/j.jhep.2023.05.028
M3 - Article
C2 - 37315809
AN - SCOPUS:85166939589
SN - 0168-8278
VL - 79
SP - 717
EP - 727
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 3
ER -